Antifibrotic effect via the regulation of transcription factor Sp1 in lung fibrosis

Area of Science:

• Molecular Biology
• Pulmonary Medicine
• Gene Therapy

Background:

• Lung fibrosis is characterized by excessive extracellular matrix (ECM) deposition.
• Transforming growth factor (TGF)-beta1 signaling is a key driver of fibrotic processes.
• Pulmonary epithelial-mesenchymal transition (EMT) contributes to lung fibrosis pathogenesis.

Purpose of the Study:

• To evaluate the antifibrotic effect of ring-type Sp1 decoy oligonucleotides (ODNs).
• To investigate the mechanism of blocking transforming growth factor (TGF)-beta1 transcription and its downstream genes.
• To assess the potential of Sp1 transcription factor as a therapeutic target for lung fibrosis.

Main Methods:

• Treatment with ring-type Sp1 decoy oligonucleotides (ODNs).
• Measurement of gene expression for TGF-beta1, metalloproteinase (MMP)-13, and fibronectin.
• Immunohistochemical analysis for alpha-smooth muscle actin (α-SMA) in lung tissue.

Main Results:

• Ring-type Sp1 decoy ODNs significantly decreased the expression of TGF-beta1, MMP-13, and fibronectin.
• Reduced expression of α-smooth muscle actin positive cells in bronchial lining and alveolar epithelium.
• Observed reduction of ECM deposition around affected lung cells.

Conclusions:

• Ring-type Sp1 decoy ODNs demonstrate significant antifibrotic effects in lung tissue.
• Blocking Sp1 transcription factor activity is a viable strategy for treating lung fibrosis.
• These findings support Sp1 as a therapeutic target for gene therapy interventions in pulmonary fibrosis.